Clinical Trials
10 trialsNCT07007767 2025-06-06
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05360264 2025-03-24
ORIENTATE
Regina Elena Cancer Institute
Phase 2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01882660 2022-12-19
DECO
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Terminated
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT02847000 2019-01-09
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT02316028 2017-10-27
DECIT
Universitair Ziekenhuis Brussel
Phase 1/2 Completed
NCT02685228 2016-02-18
SLOWDOSE001
The First Hospital of Jilin University
Phase NA Unknown
NCT00019825 2015-04-29
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
National Cancer Institute (NCI)
Phase 1 Completed
NCT00879385 2014-10-31
KRAS Wild-type Metastatic Colorectal Cancer Trial
University of Utah
Phase 1 Completed